PetMed Express (PETS) Q2’23 Missed Sales Estimate and Dividend Suspension Case

In October 2023, PetMed (PETS) released its Q2’23 financial results, missing net sales estimates and suspending quarterly dividend.
On it, $PETS fell 24.9%, losing $48M+ of shareholder value.
Investors may have grounds to suspect that PetMed hid its financial setbacks, which led to their losses.
On October 30, 2023, PetMed released its financial results for Q2’23, reporting net sales of $71 million, missing estimates by $5 million. The Company also disclosed suspension of the quarterly dividend to invest the company's cash flow in projects and initiatives with higher returns.

On this news, $PETS fell 24.9% and lost over $48 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that PetMed failed to timely disclose its financial setbacks, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.

Case Status

Attorney Investigation

Alleged Offence

Misleading Statements,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

31 October 2023

PetMed Express (PETS) Q2’23 Missed Sales Estimate and Dividend Suspension Case

Collecting participants…